ADAR1 Capital Management »

Merrimack Pharma shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Merrimack Pharma shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Merrimack Pharma

Tip: Access up to 7 years of quarterly data

All positions including Merrimack Pharma held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Merrimack Pharma by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $13M 902k 14.77
2023-12-31 $7.4M 549k 13.41

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Merrimack Pharma

JBF Capital
Goldman Sachs Group
Rise Advisors
Farther Finance Advisors

View all funds holding Merrimack Pharma